echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tide Pharma's first-class innovative drug for pneumoconiosis was approved for clinical use

    Tide Pharma's first-class innovative drug for pneumoconiosis was approved for clinical use

    • Last Update: 2022-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 8, 2022, China Biopharmaceutical Co.


    According to the official website of the Center for Drug Evaluation of the State Drug Administration, TDI01 is an oral small molecule drug with a new target and a new mechanism.


    Sino Biopharmaceutical is the first company in China to focus on ROCK2 targets


    It is expected to help 900,000 pneumoconiosis patients

    It is expected to help 900,000 pneumoconiosis patients

    By the end of 2019, about 900,000 cases of pneumoconiosis had been reported nationwide, accounting for 90% of the total number of occupational diseases.


    Xie Qirun, chairman of the board of directors of Sino Biopharmaceuticals, said that as a pharmaceutical company, it has an important mission and responsibility to pay attention to the pneumoconiosis patients.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.